Frontiers of Molecular Biology of Cancer

Stergios Boussios^{1

2

3

4}, Elisabet Sanchez¹, Matin Sheriff⁵

Affiliations

¹ Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK.
² Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, Strand, London WC2R 2LS, UK.
³ Kent Medway Medical School, University of Kent, Canterbury CT2 7LX, UK.
⁴ AELIA Organization, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece.
⁵ Department of Urology, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK.

Editorial

Stergios Boussios et al. Int J Mol Sci. 2023.

. 2023 Dec 6;24(24):17187.

doi: 10.3390/ijms242417187.

Stergios Boussios^{1

2

3

4}, Elisabet Sanchez¹, Matin Sheriff⁵

¹ Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK.
² Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, Strand, London WC2R 2LS, UK.
³ Kent Medway Medical School, University of Kent, Canterbury CT2 7LX, UK.
⁴ AELIA Organization, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece.
⁵ Department of Urology, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK.

Abstract

Cancer is rooted in genetic background, with the expression of oncogenesis playing a pivotal role in the early stages of tumor formation [...].

The authors declare no conflict of interest.

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
1. Brown J.E., Royle K.L., Gregory W., Ralph C., Maraveyas A., Din O., Eisen T., Nathan P., Powles T., Griffiths R., et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023;24:213–227. doi: 10.1016/S1470-2045(22)00793-8. - DOI - PubMed
1. Wu S., Wang Y. Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance. Altern. Ther. Health Med. 2023;17:AT8275. - PubMed
1. Boussios S., Devo P., Goodall I.C.A., Sirlantzis K., Ghose A., Shinde S.D., Papadopoulos V., Sanchez E., Rassy E., Ovsepian S.V. Exosomes in the Diagnosis and Treatment of Renal Cell Cancer. Int. J. Mol. Sci. 2023;24:14356. doi: 10.3390/ijms241814356. - DOI - PMC - PubMed
1. Pérez-Ruiz E., Melero I., Kopecka J., Sarmento-Ribeiro A.B., García-Aranda M., De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist. Updates. 2020;53:100718. doi: 10.1016/j.drup.2020.100718. - DOI - PubMed